NovaBay Pharma (NBY) Misses Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts NBY Hot Sheet
Price: $1.95 --0%
Financial Fact:
General and administrative: 2.22M
Today's EPS Names:
INM, TRI, CRVL, More
Financial Fact:
General and administrative: 2.22M
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
NovaBay Pharma (NYSE: NBY) reported Q3 EPS of ($0.10), $0.07 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $3.83 million versus the consensus estimate of $3.75 million.
For earnings history and earnings-related data on NovaBay Pharma (NBY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Shopify tanks 19% premarket as Q3 GMV, subscription revenue miss estimates
- Core Molding Technologies, Inc. (CMT) Misses Q3 EPS by 3c
- Energy Transfer (ET) Misses Q3 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
